Hanley Jr. Michael Conick
Insider CIK 1791413 · AGLE Chief Commercial Officer · ANRO Chief Operating Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience, Inc. | A Award deriv | 2026-02-11 | 2026-02-13 | 131,000 | — | $0 | 131,000 | SEC↗ |
| ANRO Alto Neuroscience, Inc. | D To issuer deriv | 2025-07-03 | 2025-07-08 | 125,000 | — | $0 | 0 | SEC↗ |
| ANRO Alto Neuroscience, Inc. | A Award deriv | 2025-07-03 | 2025-07-08 | 8,000 | — | $0 | 8,000 | SEC↗ |
| ANRO Alto Neuroscience, Inc. | A Award deriv | 2025-07-03 | 2025-07-08 | 125,000 | — | $0 | 125,000 | SEC↗ |
| ANRO Alto Neuroscience, Inc. | D To issuer deriv | 2025-07-03 | 2025-07-08 | 188,000 | — | $0 | 0 | SEC↗ |
| ANRO Alto Neuroscience, Inc. | A Award deriv | 2025-07-03 | 2025-07-08 | 188,000 | — | $0 | 188,000 | SEC↗ |
| ANRO Alto Neuroscience, Inc. | D To issuer deriv | 2025-07-03 | 2025-07-08 | 8,000 | — | $0 | 0 | SEC↗ |
| ANRO Alto Neuroscience, Inc. | A Award deriv | 2025-02-05 | 2025-02-07 | 125,000 | — | $0 | 125,000 | SEC↗ |
| ANRO Alto Neuroscience, Inc. | A Award deriv | 2024-05-20 | 2024-05-22 | 188,000 | — | $0 | 188,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2023-02-23 | 2023-02-24 | 500,000 | — | $0 | 500,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2022-08-23 | 2022-08-25 | 130,000 | — | $0 | 130,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | P Buy | 2022-06-08 | 2022-06-10 | 28,200 | $0.71 | $20.0K | 36,200 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2022-02-17 | 2022-02-22 | 160,000 | — | $0 | 160,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2021-02-17 | 2021-02-19 | 135,000 | — | $0 | 135,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2020-02-14 | 2020-02-19 | 25,000 | — | $0 | 25,000 | SEC↗ |
| AGLE Aeglea BioTherapeutics, In | A Award deriv | 2019-10-21 | 2019-10-23 | 130,000 | — | $0 | 130,000 | SEC↗ |